{
    "ticker": "FHTX",
    "name": "Foghorn Therapeutics Inc.",
    "description": "Foghorn Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with cancer and other serious diseases. Founded in 2015, Foghorn leverages its proprietary Gene Traffic Control platform to create targeted medicines that modulate the activity of chromatin, the structure that organizes DNA within cells. By understanding how chromatin influences gene expression, Foghorn aims to unlock new treatment options for cancers driven by chromatin dysregulation. The company's pipeline includes various candidates for different indications, with several programs advancing into clinical trials. Foghorn is committed to scientific excellence and aims to address unmet medical needs through its groundbreaking approach to therapeutics. The company has attracted significant investment and partnerships, allowing it to advance its research and development efforts and bring novel treatments to the market. Foghorn's mission is to improve patient outcomes by harnessing the power of epigenetics to develop next-generation therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.foghorntx.com",
    "ceo": "Vincent F. R. J. G. L. M. K. O. C. L. F. A. C. A. Z. H. V. H. T. K. K. H. C. A. K. S. Z.",
    "social_media": {
        "twitter": "https://twitter.com/FoghornTx",
        "linkedin": "https://www.linkedin.com/company/foghorn-therapeutics/"
    },
    "investor_relations": "https://investors.foghorntx.com",
    "key_executives": [
        {
            "name": "Vincent O'Neill",
            "position": "CEO"
        },
        {
            "name": "John D. G. D. J. K. J. C. A. E.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Candidates",
            "products": [
                "FHD-286",
                "FHD-409"
            ]
        }
    ],
    "seo": {
        "meta_title": "Foghorn Therapeutics Inc. | Innovative Epigenetic Therapies",
        "meta_description": "Explore Foghorn Therapeutics Inc., a leader in biopharmaceuticals dedicated to developing innovative therapies targeting chromatin modulation for cancer and other serious diseases.",
        "keywords": [
            "Foghorn Therapeutics",
            "Biotechnology",
            "Cancer Therapy",
            "Epigenetics",
            "Pharmaceuticals",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does Foghorn Therapeutics specialize in?",
            "answer": "Foghorn Therapeutics specializes in developing therapies that target chromatin to treat cancer and other serious diseases."
        },
        {
            "question": "Where is Foghorn Therapeutics headquartered?",
            "answer": "Foghorn Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "When was Foghorn Therapeutics founded?",
            "answer": "Foghorn Therapeutics was founded in 2015."
        },
        {
            "question": "What are some of Foghorn's clinical candidates?",
            "answer": "Some of Foghorn's clinical candidates include FHD-286 and FHD-409."
        },
        {
            "question": "What is Foghorn's mission?",
            "answer": "Foghorn's mission is to improve patient outcomes through innovative therapies that modulate gene expression."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO",
        "NTLA"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRNA",
        "AMGN"
    ]
}